본문 바로가기
KERD
논문KCI 등재

Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study

Mindie H. Nguyen|Ramsey Cheung|Vy H. Nguyen|Isaac Le|Audrey Ha|Richard Hieu Le|Nicholas Ajit Rouillard|Ashley Fong|Surya Gudapati|Jung Eun Park|Mayumi Maeda|Scott Barnett
대한간학회 (The korean Association for the Study of the Liver)|2023.10|Clinical and Molecular Hepatology|제29권 제4호|pp. 1002-1012

0

조회

0

다운로드

4

인용

0

참고문헌

키워드

EpidemiologyNatural historyHealth inequities

초록

Background/Aims: Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal data, we investigated the role of race and ethnicity in adverse outcomes in NAFLD patients. Methods: Patients with NAFLD confirmed by imaging via manual chart review from any clinics at Stanford University Medical Center (1995–2021) were included. Primary study outcomes were incidence of liver events and mortality (overall and non-liver related). Results: The study included 9,340 NAFLD patients: White (44.1%), Black (2.29%), Hispanic (27.9%), and Asian (25.7%) patients. For liver events, the cumulative 5-year incidence was highest among White (19.1%) patients, lowest among Black (7.9%) patients, and similar among Asian and Hispanic patients (~15%). The 5-year and 10-year cumulative overall mortality was highest for Black patients (9.2% and 15.0%, respectively, vs. 2.5–3.5% and 4.3–7.3% in other groups) as well as for non-liver mortality. On multivariable regression analysis, compared to White patients, only Asian group was associated with lower liver-related outcomes (aHR: 0.83, P=0.027), while Black patients were at more than two times higher risk of both non-liver related (aHR: 2.35, P=0.010) and overall mortality (aHR: 2.13, P=0.022) as well as Hispanic patients (overall mortality: aHR: 1.44, P=0.022). Conclusions: Compared to White patients, Black patients with NAFLD were at the highest risk for overall and non-liverrelated mortality, followed by Hispanic patients with Asian patients at the lowest risk for all adverse outcomes. Culturally sensitive and appropriate programs may be needed for more successful interventions.

Abstract

Background/Aims: Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal data, we investigated the role of race and ethnicity in adverse outcomes in NAFLD patients. Methods: Patients with NAFLD confirmed by imaging via manual chart review from any clinics at Stanford University Medical Center (1995–2021) were included. Primary study outcomes were incidence of liver events and mortality (overall and non-liver related). Results: The study included 9,340 NAFLD patients: White (44.1%), Black (2.29%), Hispanic (27.9%), and Asian (25.7%) patients. For liver events, the cumulative 5-year incidence was highest among White (19.1%) patients, lowest among Black (7.9%) patients, and similar among Asian and Hispanic patients (~15%). The 5-year and 10-year cumulative overall mortality was highest for Black patients (9.2% and 15.0%, respectively, vs. 2.5–3.5% and 4.3–7.3% in other groups) as well as for non-liver mortality. On multivariable regression analysis, compared to White patients, only Asian group was associated with lower liver-related outcomes (aHR: 0.83, P=0.027), while Black patients were at more than two times higher risk of both non-liver related (aHR: 2.35, P=0.010) and overall mortality (aHR: 2.13, P=0.022) as well as Hispanic patients (overall mortality: aHR: 1.44, P=0.022). Conclusions: Compared to White patients, Black patients with NAFLD were at the highest risk for overall and non-liverrelated mortality, followed by Hispanic patients with Asian patients at the lowest risk for all adverse outcomes. Culturally sensitive and appropriate programs may be needed for more successful interventions.

참고문헌 (41)

  1. Bedossa P, "Pathology of non-alcoholic fatty liver disease", Liver Int, 37(Suppl 1), pp.85~89 (2017)
  2. Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
  3. Miele L, "Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease", Metabolism, 112, pp.154355~ (2020)
  4. Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
  5. Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
  6. Bril F, "Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients", Liver Int, 35, pp.2139~2146 (2015)
  7. Stern C, "Non-invasive diagnosis of hepatic steatosis", Hepatol Int, 11, pp.70~78 (2017)
  8. Karlas T, "Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis", J Hepatol, 66, pp.1022~1030 (2017)
  9. de Lédinghen V, "Controlled attenuation parameter(CAP)with the XL Probe of the Fibroscan® : A comparative study with the M probe and liver biopsy", Dig Dis Sci, 62, pp.2569~2577 (2017)
  10. Gu J, "Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease : a meta-analysis", Eur Radiol, 29, pp.3564~3573 (2019)
  11. Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1264~1281 (2019)
  12. Long MT, "Advances in non-invasive biomarkersfor the diagnosis and monitoring of non-alcoholic fatty liver disease", Metabolism, 111S, pp.154259~ (2020)
  13. Davison BA, "Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials", J Hepatol, 73, pp.1322~1332 (2020)
  14. Agbim U, "Non-invasive assessment of liver fibrosis and prognosis : an update on serum and elastography markers", Expert Rev Gastroenterol Hepatol, 13, pp.361~374 (2019)
  15. Petroff D, "Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes : an individual patient data meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.185~198 (2021)
  16. Kechagias S, "Established and emerging factors affecting the progression of nonalcoholic fatty liver disease", Metabolism, 111S, pp.154183~ (2020)
  17. Kim D, "Race", ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016, 2019, pp.13, 205~213
  18. Le MH, "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States", PLoS One, 12, pp.e0173499~ (2017)
  19. Le MH, "Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016", J Intern Med, 287, pp.711~722 (2020)
  20. Arshad T, "Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016", Hepatol Commun, 5, pp.1676~1688 (2021)
  21. Otgonsuren M, "Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease", Dig Dis Sci, 58, pp.1132~1140 (2013)
  22. Flores YN, "Risk factorsfor chronic liver disease in Blacks, Mexican Americans, and Whites in the United States : results from NHANES IV, 1999-2004", Am J Gastroenterol, 103, pp.2231~2238 (2008)
  23. Ong JP, "Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease", J Hepatol, 49, pp.608~612 (2008)
  24. "National Center for Health Statistics, Centers for Disease Control and Prevention, Department of Health and Human Services"[URL]
  25. Rich NE, "Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States : A systematic review and meta-analysis", Clin Gastroenterol Hepatol, 16, pp.198~210 (2018)
  26. Setiawan VW, "Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups : The multiethnic cohort", Hepatology, 64, pp.1969~1977 (2016)
  27. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
  28. Agbim U, "Ethnic disparities in adiposity : Focus on non-alcoholic fatty liver disease, visceral, and generalized obesity", Curr Obes Rep, 8, pp.243~254 (2019)
  29. Yang TC, "Neighborhood effects on body mass : Temporal and spatial dimensions", Soc Sci Med, 217, pp.45~54 (2018)
  30. Leslie T, "Survey of health status, nutrition and geography of food selection of chronic liver disease patients", Ann Hepatol, 13, pp.533~540 (2014)
  31. Paik JM, "Dietary risks for liver mortality in NAFLD : Global burden of disease data", Hepatol Commun, 6, pp.90~100 (2022)
  32. Noureddin M, "NASH leading cause of liver transplant in women : Updated analysis of indications for liver transplant and ethnic and gender variances", Am J Gastroenterol, 113, pp.1649~1659 (2018)
  33. Estevez J, "Clinical features associated with survival outcome in AfricanAmerican patients with hepatocellular carcinoma", Am J Gastroenterol, 114, pp.80~88 (2019)
  34. Post WS, "Racial and ethnic differences in all-cause and cardiovascular disease mortality : The MESA study", Circulation, 146, pp.229~239 (2022)
  35. Weight N, "Socioeconomic disparitiesin the management and outcomes of acute myocardial infarction", Heart (2023)[DOI]
  36. Peterson K, "Mortality disparities in racial", ethnic minority groups in the veterans health administration : An evidence review and map, 2018, pp.108, e1~e11
  37. Kardashian A, "Health disparitiesin chronic liver disease", Hepatology, 77, pp.1382~1403 (2023)
  38. Bailey ZD, "How structural racism works-Racist policies as a root cause of U. S. racial health inequities", N Engl J Med, 384, pp.768~773 (2021)
  39. Golabi P, "Prevalence and outcomes of non-alcoholic fatty liver disease(NAFLD)among Asian American adults in the United States", Liver Int, 39, pp.748~757 (2019)
  40. Kim NG, "Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma : A real-world experience from 1998 to 2015", Cancer, 124, pp.2588~2598 (2018)
  41. Song SJ, "Can we use old NAFLD data under the new MASLD definition?", J Hepatol (2023)[DOI]

관련 논문AI추천

Global incidence of adverse clinical events in nonalcoholic fatty liver disease: A systematic review and meta-analysisChristopher D. Stave, David M. Le, Fanpu Ji, Hansen Dang, KeeSeok Lee, Michael H. Le, Mindie H. Nguyen, Ramsey Cheung, Takanori Ito, Thomas C. Baez, Vy H. Nguyen, Yee Hui Yeo, Yuankai Wu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제2호Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal realworld study”Mindie H. Nguyen, Vy H. Nguyen대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Racial and ethnic disparities in metabolic dysfunctionassociated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of nonalcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”Jae Hyun Bae대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”Jae Hyun Bae대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populationsAijaz Ahmed, Donghee Kim, Kanokphong Suparan, Karn Wijarnpreecha, Pojsakorn Danpanichkul, Vitchapong Prasitsumrit대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Mortality and Cardiovascular Outcomes in Patients with MAFLD Compared with Patients with MASLD: A Systematic Review and Meta-AnalysisAn Jihyun, Kim Seon-Ok, Kim Ye Rim, Na Seong Kyun, Shim Ju Hyun, Yang Jiwon거트앤리버 소화기연관학회협의회 · Gut and Liver2026 · 제20권 제1호

이 간행물의 다른 논문 (22건)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernityJoon Ho Moon, 김원, Gi-Ae Kimpp. 831-843Waiting for the changes after the adoption of steatotic liver disease전대원, Eileen L. Yoonpp. 844-850Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapyTakako Inoue, Yasuhito Tanaka, Takehisa Watanabepp. 851-868Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harmYao-Chun Hsu, Jia-Horng Kao, Cheng-Hao Tsengpp. 869-890Hepatorenal syndrome: Current concepts and future perspectivesChan-Young Jung, Jai Won Changpp. 891-908
원문 보기